FDG-PET/CT useful in evaluating response to melanoma drugs

01/11/2012 | AuntMinnie.com (free registration)

Patients with melanoma who had partial metabolic response to bevacizumab plus ipilimumab, determined through FDG-PET/CT scans, had longer disease-free survival compared with patients who had stable or progressive metabolic disease, according to Dana-Farber Cancer Institute researchers. "While the results are preliminary and further studies are needed, these results suggest both contrast-enhanced CT and FDG-PET may be important imaging biomarkers of efficacy for these therapeutic targets in this clinical setting," said researcher Dr. Pamela DiPiro.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX